Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2002-05-23
2010-11-02
Ketter, James S (Department: 1636)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C435S006120
Reexamination Certificate
active
07825094
ABSTRACT:
Novel methods of treating proliferative disorders characterized by elevated Her-2, and the patient is then administered an effective amount of an HSP90 inhibitor.
REFERENCES:
patent: 4261989 (1981-04-01), Sasaki et al.
patent: 5387584 (1995-02-01), Schnur
patent: 5650430 (1997-07-01), Sugimura et al.
patent: 5932566 (1999-08-01), Schnur et al.
patent: 5968921 (1999-10-01), Gold
patent: 6210974 (2001-04-01), Gold
patent: 6239168 (2001-05-01), Ino et al.
patent: 6335157 (2002-01-01), Gonzalez et al.
patent: 6413975 (2002-07-01), Chasin et al.
patent: 6440982 (2002-08-01), Maw et al.
patent: WO 96/32480 (1996-10-01), None
patent: WO 96/40789 (1996-12-01), None
patent: WO 97/04801 (1997-02-01), None
patent: WO 98/51702 (1998-11-01), None
patent: WO 00/61578 (2000-10-01), None
Workman, P. Auditing the Pharmacological Accounts for Hsp90 Molecular Chaperone Inhibitors: Unfolding the Relationship between Pharmacokinetics and Pharmacodynamics, Molecular Cancer Therapeutics 2:131-138, 2003.
Wu, T. Analysing Gene Expression Data from DNA Microarrays to Identify Candidate Genes, J. Pathol. 195(1):53-65, 2001.
Lucitini, J. Gene Association Studies Typically Wrong, The Scientist 18(24):20, 2004.
Chen, G. et al. Discordant Protein and mRNA Epxression in Lung Adenocarcinomas, Molecular and Cellular Proteomics 1:304-313, 2002.
Isaacs, J. et al. Heat Shock Protein 90 as a Molecular Target for Cancer Therapeutics, Cancer Cell 3:213-217, 2003.
Roe, S.M. et al. Structural Basis for Inhibition of the Hsp90 Molecular Chaperone by the Antitumor Antibiotics Radicicol and Geldanamycin, J. Med. Chem. 42:260-266, 1999.
Chiosis, G. et al. A Small Molecule Designed to Bind to the Adenine Nucleotide Pocket of Hsp90 Causes Her2 Degradation and the Growth Arrest and Differentiation of Breast Cancer Cells, Chemistry & Biology 8:289-299, 2001.
Tommasi et al. (1992) Tumori 78:106-110.
Kelland et al. (1999) J. Natl. Cancer Inst. 91:1940-1949.
Mandler et al. (2000) J. Natl. Cancer Inst. 92:1573-1581.
Tokuda et al. (1999) Br. J. Cancer 81:1419-1425.
Münster et al. (2002) Cancer Res. 62:3132-3137.
Bamberger et al., Inhibition of mineralocorticoid and glucocorticoid receptor function by the heat shock protein 90-binding agent geldanamycin, Molecular and Cellular Endocrinology, 1997, pp. 233-240, vol. 131, No. 2.
Black et al., Reactions of Ninhydrin with Activated Anilines: Formation of Indole Derivatives, 1994, pp. 10983-10994, vol. 50, No. 37, See Compound 17.
Bohen, Genetic and Biochemical Analysis of p23 and Ansamycin Antibiotics in the Function of HSP9O-Dependent Signaling Proteins, Molecular and Cellular Biology, 1998, pp. 3330-3339, vol. 18, No. 6.
Chavany et al., p185erbB2Binds to GRP94 in Vivo, Journal of Biological Chemistry, 1996, pp. 4974-4977, vol. 271, No. 9.
Chen et al., The Ah Receptor is a Sensitive Target of Geldanamycin-Induced Protein Turnover, Archives of Biochemistry and Biophysics, 1997, pp. 190-198, vol. 348, No. 1.
Kato et al., Synthesis of Compounds related to Antitumor Agents. IV. On The Reaction of Aromatic Carboxylates with 2,4 Diamino-5-hydroxy-6-methylpyrimidine, 1976, pp. 2461-2469, , vol. 24, No. 10, Publisher: See Table 2.
Landel et al., Estrogen Receptor Accessory Proteins Augment Receptor—DNA Interaction and DNA Bending, The Journal of Steroid Biochemistry & Molecular Biology, 1997, pp. 59-73, vol. 63, No. 1-3.
Munster et al., Inhibition of Heat Shock Protein 90 Function by Ansamycins Causes the Morphological and Functional Differentiation of Breast Cancer Cells, Cancer Research, 2001, pp. 2945-2952, vol. 61.
Neckers, L., Effects of Geldanamycin and Other Naturally Occurring Small Molecule Antagonists of Heat Shock Protein 90 on HER2 Protein Expression, Breast Disease, 2000, vol. 11, pp. 49-59.
Pratt, The hsp90-based Chaperone System: Involvement in Signal Transduction from a Variety of Hormone and Growth Factor Receptors, Proceedings of the Society for Experimental Biology and Medicine, 1998 , pp. 420-434, vol. 217, No. 4.
Rosenhagen et al., Synergistic Inhibition of the Glucocorticoid Receptor by Radicicol and Benzoquinone Ansamycins, Biol. Chem., 2001, pp. 499-504, vol. 382.
Scheibel et al., Two chaperone sites in Hsp90 differing in substrate specificity and ATP dependence, Proceedings of the National Academy of Sciences, , pp. 1495-1499, vol. 95, No. 4.
Schnur et al., erbB-2 Oncogene Inhibition by Geldanaymycin Derivatives: Synthesis, Mechanism of Action, and Structure—Activity Relationships, J. Med. Chem., 1995, pp. 3813-3820, vol. 38.
Schulte et al., The benezoquinone ansamycin 17-allylamino-17-demethoxygeldanamycin binds to HSP90 and shares important biologic activities with geldanamycin, Cancer Chemotherapy and Pharmacology, 1998, pp. 273-279, vol. 42.
Segnitz et al., The Function of Steroid Hormone Receptors Is Inhibited by the hsp90-specific Compound Geldanamycin, The Journal of Biological Chemistry, 1997, pp. 18694-18701, vol. 272, No. 30.
Stebbins et al., Crystal Structure of an Hsp9O-Geldanamycin Complex:: Targeting of a Protein Chaperone by an Antitumor Agent, Molecular Biology, 1997, pp. 239-250, vol. 89.
Stockwell et al., High-throughput screening of small molecules in miniaturized mammalian cell-based assays involving post-translational modifications, Chemistry and Biology, 1999, pp. 71-83, vol. 6.
Zheng F F et al., “Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases.” Cancer Research. Apr. 15, 2000, pp. 2090-2094, vol. 60, No. 8.
Hartmann F et al., “Effects of the tyrosine-kinase inhibitor geldanamycin on ligand-induced Her-2
eu activation, receptor expression and proliferation of Her-2-positive malignant cell lines.” International Journal of Cancer. Jan. 17, 1997, pp. 221-229, vol. 70 No. 2.
An W G et al., “Depletion of P185ERBB2, RAF-1 and Mutant P53 Proteins by Geldanamycin Derivatives Correlates with Antiproliferative Activity.” Cancer Chemotherapy and Pharmacology, Springer Verlag. 1997, pp. 60-64, vol. 40, No. 1.
Supko J G et al., “Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent.” Cancer Chemotherapy and Pharmacology. 1995, pp. 305-315, vol. 36, No. 4.
Schnur et al., “Inhibition of the Oncogene Product p185erb-b2 in Vitro and in Vivo by Geldanamycin and Dihydrogeldanamycin Derivatives.” Journal of Medicinal Chemistry, American Chemical Society. 1995. pp. 3806-3812, vol. 38, No. 19.
Smith D F et al., “Molecular chaperones, Biology and prospects for pharmacological intervention.” Pharamcological Reveiws. 1998. pp. 493-513, vol. 50, No. 4.
Smith V et al., “The effect of overexpression of C-ERBB2 on the chemosensitivity of a human ovarian carcinoma cell line.” British Journal of Cancer. 2001. p. 100, #P263, vol. 85, No. Supplement 1 XP008064337.
Munster Pamela
Rosen Neal
Ketter James S
Larson & Anderson LLC
Sloan-Kettering Institute for Cancer Research
LandOfFree
Method of treatment for cancers associated with elevated HER... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treatment for cancers associated with elevated HER..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treatment for cancers associated with elevated HER... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4244808